ERBB2 and breast cancer: Importantly, mucolytic treatment N-Acetylcysteine (NAC) restored the impaired HER2 accessibility caused by MUC4, and consequently enhanced the binding and uptake of 89Zr-Trastuzumab in vitro and in vivo in a MUC4-expressing HER2-positive BC xenograft mouse model [19].